TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06527274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Myopic defocus soft lens design (MDSL)
Description: An optical device designed to provide a myopic defocus to control myopia progression

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Single vision soft lens design (SVSL
Description: An optical device designed to correct refractive error like myopia
Study: NCT05640427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The same capacity of 0.9% normal saline was used in group C
Study: NCT05280054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: 360 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: 360 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 1000 mg oral
Study: NCT06183970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AssistI patients
Description: The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habilect patients
Description: The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
Study: NCT04088942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity smoking cessation intervention
Description: 1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity smoking cessation intervention
Description: Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
Study: NCT04783038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distance Reiki
Description: Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham distance Reiki
Description: Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
Study: NCT06493084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAE102 injection
Description: intravenous drip or subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous drip or subcutaneous injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intravenous drip or subcutaneous injection
Study: NCT06306014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period
Study: NCT06560684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral F/TDF Pills
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral F/TDF Pills
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV rectal douche
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV rectal douche
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
Study: NCT04610970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525 tablets
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study: NCT04752384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Mucositis (OM) Pain App
Description: Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.
Study: NCT06554067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: Ten minutes of active transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial direct current stimulation
Description: Ten minutes of active transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active vagus nerve stimulation
Description: Ten minutes of active vagus nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active vagus nerve stimulation
Description: Ten minutes of active vagus nerve stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Ten minutes of sham tDCS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Ten minutes of sham tDCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Ten minutes of sham VNS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Ten minutes of sham VNS
Study: NCT05724030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: integrated pulmonary index
Description: integarted pumobary index monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: integrated pulmonary index
Description: integarted pumobary index monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: saturation
Description: saturation monitorization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saturation
Description: saturation monitorization
Study: NCT04830254

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS) device
Description: The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
Study: NCT06057506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paranix® Shampoo
Description: well established medical device for the treatment of head lice infestation (osmolone based)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paranix® Lotion
Description: well established medical device for the treatment of head lice infestation (dimethicone based)
Study: NCT04830254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS) device
Description: The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
Study: NCT06314256

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: İnterdental papilla will be injected by i-PRF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
Study: NCT06189742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
Study: NCT04735939

Intervention type: RADIATION
Intervention: radiotherapy
Description: Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.

Intervention type: RADIATION
Intervention: radiotherapy
Description: Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
Study: NCT05249179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral stimulation
Description: Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral stimulation
Description: Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
Study: NCT06466356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational Course for Suicide Prevention
Description: Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy session
Description: Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
Study: NCT04899492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: 1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: 1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: 1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
Study: NCT04816890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1 Pram P037
Description: Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Subcutaneous administration of insulin lispro in combination with a basal insulin.
Study: NCT04899492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
Study: NCT04201028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Health Coaching with devices
Description: Devices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Health Coaching with no devices
Description: No Devices
Study: NCT04554147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! App-enhanced Hypertension Intervention
Description: FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention.
Study: NCT06437184

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ODP
Description: se previously
Study: NCT06130696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamshell exercises
Description: Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric and muscle strengthen exercise
Description: group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given
Study: NCT05647356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: Bicalutamide at a dose of 50mg once daily for 28 days.
Study: NCT06541119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective Peroneus longus excercise
Description: Weight bearing peroneus longus exercise
Study: NCT05356624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
Study: NCT05511649

Intervention type: DEVICE
Intervention: continuous electronic monitor
Description: All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
Study: NCT05655390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Intervention Planning
Description: The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
Study: NCT05668429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: carbon-14 (\[14\^C\])-Ibrexafungerp